In a more recent study by Snyder and colleagues, intra-tumoral injections of necroptotic cells (by engineering constitutively active forms of RIPK3), but not apoptotic cells, into B16 tumors induced BATF3 cDC1 and CD8+ T cell-dependent anti-tumor immunity via the RIP1/RIP3/NF-κB pathway independently of cell lysis [114]. The gene discussed is RIPK3; the disease is neoplasm.